Protox signs exclusive Lung Cancer licence agreement and initiates Lung Cancer study
11-Aug-2005
The Company also announced that it has initiated a preliminary non-small cell lung cancer study with PORxin(TM) antibody fusion constructs at the BC Cancer Agency. As reported earlier, this lung cancer project has received a financial contribution of up to $340,000 from the National Research Council (NRC) Industrial Research Assistance Program (IRAP).
Most read news
Topics
lung cancer
National Research Council
University of Victoria
Protox Therapeutics
IBS
BC Cancer Agency
Organizations
National Research Council of Canada
Protox Therapeutics
University of Victoria
Innovation and Development
BC Cancer Agency
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.